

Additional table. Characterization of IgA-anti-TG1 and IgA-anti-TG3 seropositive cases.

Patient no.	Age (y)	Sex	IgA-anti-TG2 (pos >10 U/ml)	IgA-anti-TG1 (pos >37.3 AU)	IgA-anti-TG3 (pos > 48.4 AU)	IgA-anti-DGP (pos > 10 U/ml)	Clinical presentation
Atopic dermatitis							
AT002	10	F	0.7	15.2	49.3*	0.3	
AT048	9	F	0.6	10.5	55.2	0.9	
AT052	4	F	0.1	19.7	60.5	0.3	
AT215	6	M	0.2	60.0	19.0	0.8	asthma
AT219	3	M	0.0	20.2	56.5	0.7	allergic rhinoconjunctivitis, asthma
AT247	18	F	0.5	42.8	34.4	0.9	allergic rhinoconjunctivitis, asthma
AT250	8	F	0.1	16.8	102.8	1.7	
AT266	3	M	0.2	47.2	39.6	0.5	
AT267	18	M	0.4	188.6	134.6	1.7	allergic rhinoconjunctivitis, asthma, urticaria
AT298	12	F	1.0	31.3	50.2	1.1	allergic rhinoconjunctivitis, asthma
AT329	2	F	0.2	16.2	57.1	0.3	
AT361	17	F	0.4	30.4	75.9	1.1	
AT380	6	M	0.1	70.0	12.0	1.4	
AT381	2	M	0.4	50.0	12.0	1.2	
Atopic dermatitis and concomitant coeliac disease							
AT018	7	F	128	95.2	0	11.5	silent coeliac disease, allergic rhinitis, asthma
AT091	3	F	>128	40.5	3.5	142.0	silent coeliac disease
Coeliac disease							
TT006	10	M	128.0	51.8	31.1	84.1	atypical gastrointestinal coeliac disease
CD08	10	M	117	46.6	17.1	9.9	classical coeliac disease; type 1 diabetes
CD34	9	F	160	79.5	104.8	25.0	classical coeliac disease; type 1 diabetes
CD45	11	M	152	8.7	104.7	15.0	silent coeliac disease
VA4	1	F	73.9	161.6	94.3	128.0	classical coeliac disease
VA27	7	F	128	276.3	95.0	128.0	classical coeliac disease; type 1 diabetes
VA28	1	F	13.5	48.2	37.5	128.0	classical coeliac disease
VA36	15	M	128	129.0	1039.5	128.0	classical coeliac disease
VA40	8	F	59.2	43.6	15.7	128.0	classical coeliac disease; type 1 diabetes
VA67	14	F	60.6	42.0	26.3	15.0	classical coeliac disease; type 1 diabetes
VA69	1	F	76.2	117.8	41.6	128.0	classical coeliac disease
Control group							
TT009	0.5	F	0.0	63.8	60.2	1.7	cystic fibrosis, diarrhoea
TT031	10	F	0.2	55.9	14.2	2.9	gastritis (<i>H. pylori</i>)
TT053	13	M	0.7	25.5	91.9	1.1	gastritis (<i>H. pylori</i>)

*Values marked in bold – positive values for IgA-anti-TG2 and IgA-anti-DGP (based on manufacturer's recommendations) and for IgA-anti-TG1 and IgA-anti-TG3 (based on the mean+2SD in control subjects).